How to properly plan inclusion and exclusion criteria in a study? How to identify which of them may pose the greatest challenges and how to address them?
Proper planning of inclusion and exclusion criteria is one of the key elements of a study protocol—it directly affects participant safety, data quality, and recruitment timelines. Well-designed criteria should ensure a homogeneous and appropriate population for evaluating endpoints, while also being operationally feasible (verifiable at study sites without excessive burden and without artificially narrowing the patient pool).
At the planning stage, it is essential to clearly link the criteria to the study objective, the mechanism of action of the investigational product or medical device, and the clinical risk profile. Inclusion criteria define the population whose outcomes will be interpreted, so they should cover the most important disease characteristics (e.g., diagnosis, stage, duration) and conditions that allow for a reliable assessment of safety and efficacy. Exclusion criteria, in turn, are intended to eliminate situations that increase risk (e.g., significant comorbidities, contraindications), confound outcome assessment (e.g., concomitant therapies, recent participation in another trial), or make protocol compliance unlikely.
For criteria to be “correct” in practice, they must be clear, measurable, verifiable in medical records, and worded to minimize interpretation. A good rule of thumb is to formulate them so that a site can answer “yes” or “no” without additional explanation. If a criterion requires subjective assessment (e.g., “stable patient condition”), it should be specified further (e.g., defining the duration of stable treatment or no dose changes). It is also crucial to harmonize definitions and verification methods across the protocol, eCRF, and operational documents (e.g., qualification guidelines, monitoring plan) to avoid inconsistencies and queries during the study.
To determine which criteria may be the most challenging, a risk-based approach and operational feasibility testing are recommended. In practice, each criterion should be assessed in terms of: (1) impact on the size of the eligible patient pool, (2) difficulty of verification, (3) risk of incorrect eligibility determination, and (4) risk of generating a high number of protocol deviations. The most challenging criteria are usually those that significantly narrow the population (e.g., narrow time windows from diagnosis, biomarkers not routinely assessed in standard practice, requirements regarding prior lines of therapy), require tests not routinely available (specialized assays, imaging in specific standards), or rely on data that are often incomplete in medical records (e.g., detailed treatment history, exact dates, results from many months earlier).
How can these challenges be addressed? First, conduct a robust feasibility assessment before finalizing the protocol—ideally using real site data or population reviews (e.g., how many such patients sites see per month and whether they meet specific conditions). Second, where possible, replace “ideal” requirements with “sufficient” ones—criteria that still protect safety and data quality but do not hinder recruitment (e.g., wider time windows, allowing stable comorbidities, adjusting laboratory thresholds if they are not critical). Third, limit the number of criteria to those that are truly necessary—an excessive number of criteria rarely improves study quality but significantly increases screen failure rates, costs, and timelines.
It is also good practice to plan tools that reduce the risk of eligibility errors: qualification checklists, clear interpretation algorithms, pre-screening reviews, and consistent mapping of criteria to eCRF fields. In higher-risk studies, additional central verification of selected criteria (e.g., key laboratory results, imaging, biomarkers) may also be implemented. This provides greater support to sites and helps sponsors minimize the risk of incorrect participant inclusion.
In summary, proper planning of inclusion and exclusion criteria means finding the right balance between scientific rigor and feasibility. The greatest challenges should be identified early by analyzing their impact on recruitment and the ability to verify them reliably at study sites. Well-thought-out criteria result in fewer screen failures, fewer deviations, faster recruitment, and—most importantly—data you can trust.
Looking for support in study planning? Schedule a meeting with our expert, who will help you design inclusion and exclusion criteria in the most effective way.
